All of the included studies were observational cohort studies. Each study included pregnant women with either gestational diabetes or pregestational diabetes who were on insulin glargine and a control ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...

SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- and long-acting insulins.

The use of insulin glargine, (a single injection of daily insulin) is as effective at controlling blood sugar for people with diabetes as insulin lispro (which has to be injected up to three times a ...

The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Lantus (insulin glargine) and a possible increased risk of cancer. Lantus is a long-acting ...

March 11, 2011 — Insulin degludec (Novo Nordisk), a novel, ultra-long-acting basal formulation, provides comparable glycemic control to insulin glargine without additional adverse events and may ...

Basaglar (insulin glargine) is a brand-name drug that’s used to help manage blood sugar levels in certain people. The drug comes as a liquid solution that’s injected under your skin. It’s usually ...

As part of the Biosimilars Initiative, British Columbia, Canada, implemented a mandatory switch to biosimilar insulin glargine for patients covered by the province’s drug plan. Multiple Canadian ...

CHICAGO, June 29 (Reuters) - Dr. Louis Philipson has already started fielding calls from worried diabetics after new studies of 300,000 patients released on Friday suggested the Sanofi-Aventis insulin ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...